Johnson & Johnson (NYSE:JNJ) Stock Price Up as Sentiment Improves, now at 0.87

May 16, 2018 - By Rebecca Betts

Johnson & Johnson (NYSE:JNJ) Corporate Logo

Johnson & Johnson’s Sentiment

In 2017 Q4 Johnson & Johnson (NYSE:JNJ) big money sentiment increased to 0.87, SEC filings reveal. So its up 0.04, from 2017Q3’s 0.83. 797 investment professionals increased and opened new positions, while 919 reduced and sold positions in Johnson & Johnson so the sentiment increased. These funds own 1.72 billion shares, that’s up from 1.71 billion shares in 2017Q3. Funds holding Johnson & Johnson in top 10 changed to 572 from 580 for a decrease of 8. 35 Investors Sold All; 884 Reduced Holdings; 654 increased holdings while 143 investment professionals bought holdings.

Most Johnson & Johnson Shareholders

As of 2017 Q4 Robert Wood Johnson Foundation has 100% invested in Johnson & Johnson. As of 2017 Q4, 25,000 shares of Johnson & Johnson are owned by Cincinnati Indemnity Co. Moreover, Pettee Investors Inc. reported 145,012 shares in Johnson & Johnson equivalent to 12.29% of its US long stock exposure. Armstrong Henry H Associates Inc revealed 501,392 shares position in Johnson & Johnson. The Georgia-based fund Boulegeris Investments Inc. looks positive on Johnson & Johnson, possessing 125,211 shares.

Johnson & Johnson, together with its subsidiaries, researches and develops, makes, and sells various products in the health care field worldwide.The firm is worth $337.36 billion. It operates through three divisions: Consumer, Pharmaceutical, and Medical Devices.The P/E ratio is 265.36. The Consumer segment offers baby care products under the JOHNSONÂ’S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSONÂ’S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

JNJ is touching $125.78 during the last trading session, after increased 0.52%.Currently Johnson & Johnson is uptrending after 1.12% change in last May 16, 2017. JNJ has 1.54 million shares volume. The stock underperformed the S&P500 by 10.43%.

On July, 17 is awaited Johnson & Johnson (NYSE:JNJ)’s earnings report, as reported by Faxor. Analysts forecast $2.05 EPS, which is $0.22 up or 12.02 % from 2017’s $1.83 EPS. JNJ’s profit could reach $5.50 billion with 15.34 P/E in case $2.05 EPS is published. Wall Street now predicts -0.49 % negative EPS growth despite Johnson & Johnson last quarter’s EPS of $2.06.

Cullen Frost Bankers Inc holds 197,732 shs. 32,337 are held by Family Corp. Forte Capital Ltd Limited Liability Company Adv reported 0.67% of its capital in Johnson & Johnson (NYSE:JNJ). Bartlett And Limited Company accumulated 196,715 shs or 1.09% of the stock. Mai has invested 1.31% of its capital in Johnson & Johnson (NYSE:JNJ). Lourd Ltd Llc holds 0.19% of its capital in Johnson & Johnson (NYSE:JNJ) for 21,384 shs. Hwg Holdg Lp holds 0.01% of its capital in Johnson & Johnson (NYSE:JNJ) for 57 shs. Private Wealth Prtn Limited Com holds 0.81% or 31,236 shs in its capital. Mitchell Capital Communication holds 0.13% of its capital in Johnson & Johnson (NYSE:JNJ) for 2,636 shs. Tru Of Vermont holds 183,152 shs. Cornerstone reported 132,700 shs. 33,124 were reported by Colony Gru Ltd Liability. Atalanta Sosnoff Lc holds 2.11% in Johnson & Johnson (NYSE:JNJ) or 465,222 shs. Fisher Asset Limited Liability holds 2.21% of its capital in Johnson & Johnson (NYSE:JNJ) for 12.13 million shs. Pettee Invsts has 12.29% invested in Johnson & Johnson (NYSE:JNJ).

Johnson & Johnson registered $20.17 million net activity with 0 insider buys and 1 insider sale since February 15, 2018.

Johnson & Johnson (NYSE:JNJ) Ratings Coverage

In total 10 analysts cover Johnson & Johnson (NYSE:JNJ). “Buy” rating has 5, “Sell” are 1, while 4 are “Hold”. 50% are bullish. 17 are the (NYSE:JNJ)’s analyst reports since January 2, 2018 according to StockzIntelligence Inc. On Thursday, April 12 the rating was upgraded by Credit Suisse to “Buy”. On Tuesday, February 27 the rating was maintained by Citigroup with “Neutral”. On Tuesday, April 10 the stock has “Equal-Weight” rating by Morgan Stanley. On Tuesday, February 6 the firm has “Buy” rating by Wells Fargo given. On Tuesday, January 16 the stock has “Buy” rating by Jefferies. On Friday, March 23 the stock has “Buy” rating by Jefferies. On Wednesday, April 18 Leerink Swann maintained Johnson & Johnson (NYSE:JNJ) with “Buy” rating. On Monday, February 26 the company was maintained by Jefferies. On Friday, April 13 the rating was maintained by Jefferies with “Buy”. On Wednesday, April 18 Stifel Nicolaus maintained Johnson & Johnson (NYSE:JNJ) with “Hold” rating.

For more Johnson & Johnson (NYSE:JNJ) news released briefly go to: Finance.Yahoo.com, Seekingalpha.com, Seekingalpha.com, Seekingalpha.com or Livetradingnews.com. The titles are as follows: “Johnson & Johnson Stock Looks Attractive on the Big Dip” released on May 10, 2018, “Johnson & Johnson: Waiting On The Wave” on May 11, 2018, “Johnson & Johnson Sells Off After Earnings” with a publish date: April 22, 2018, “What Can I Expect To Make If I Invest In Johnson & Johnson Today?” and the last “Johnson & Johnson (NYSE:JNJ) Stock Oversold” with publication date: May 03, 2018.

Johnson & Johnson (NYSE:JNJ) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.